Latest Marketable Securities News

Memphasys has rapidly established a foothold in the UK IVF market, securing four active commercial trials and initial orders for its Felix™ sperm selection system within weeks of launch. This momentum aligns with its global expansion strategy targeting major fertility markets.

Dexus Convenience Retail REIT reports a 1.1% net valuation uplift for H1 2026 and increases its on-market buy-back target to 5% of securities, signalling confidence in its portfolio and capital management.

Dexus Industria REIT's portfolio valuation edged up by $3.2 million at mid-2026, while the REIT increased its securities buy-back target to 5%, signalling confidence amid stable industrial market conditions.

Dexus Convenience Retail REIT has agreed to sell three convenience retail assets for $8 million, achieving a 1.4% premium to book value, with proceeds earmarked for its on-market buy-back program.

Australian Strategic Materials Limited (ASM) shareholders are set to vote on a scheme of arrangement for Energy Fuels Inc. to acquire 100% of ASM shares and options, offering a significant premium and exposure to a vertically integrated rare earth supply chain.

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.

Novo Resources narrowed its Q1 2026 net loss to CAD 685K, boosted cash to CAD 10.6M following a $5.9M placement, and outlined aggressive gold and antimony drilling campaigns in Australia.

Freehill Mining has secured and reviewed the Mineral Resource Estimate block model for its Blanco y Negro copper-gold project in Chile, enabling accelerated underground mine planning and highlighting growth potential amid a strengthening copper market.

EBR Systems accelerated its U.S. commercial rollout of the WiSE CRT System in Q1 2026 with implant volumes more than doubling and revenue hitting US$2.4 million. The company also secured a key regulatory milestone in Australia with TGA Priority Review, yet losses deepened and cash burn intensified, raising fresh questions about its funding runway.

Block, Inc. reported a robust Q1 2026 with AI-powered productivity gains, strong Cash App and Square growth, and a $5 billion share buyback boost. Despite a GAAP net loss due to restructuring and legal costs, the fintech giant raised its full-year outlook, signaling confidence in its AI-led transformation.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.